Detalhe da pesquisa
1.
Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
Ann Oncol
; 33(10): 989-991, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35964823
Mostrar mais
Texto completo
2.
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
Br J Cancer
; 115(10): 1157-1173, 2016 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27736844
3.
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.
Br J Cancer
; 107(7): 1025-30, 2012 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-22910320
4.
Optimal treatment for relapsing ovarian cancer.
Ann Oncol
; 21 Suppl 7: vii218-22, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20943618